Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coliin Taiwan

Table 1 Antimicrobial susceptibility testing results for carbapenem-non-susceptible E. coli isolates in 2010 and 2012

Antibiotics	ertapenem-non-susceptible *E. coli* (8 hospitals) and imipenem- or meropenem-non-susceptible E. coli (17 hospitals)
	2010 (n = 32)				2012 (n = 43)
	MIC range (μg/ml)	MIC₅₀(μg/ml)	MIC₉₀(μg/ml)	Resistance (%)	MIC range (μg/ml)	MIC₅₀(μg/ml)	MIC₉₀(μg/ml)	Resistance (%)
Ertapenem	2- ≥ 8	≥8	≥8	100	1- ≥ 8	≥8	≥8	100
Imipenem	1- ≥ 8	4	≥8	56.3	1- ≥ 8	≥8	≥8	72.1
Meropenem	0.12- ≥ 8	2	8	31.3	0.5- ≥ 8	4	≥8	58.1
Doripenem	0.12- ≥ 4	1	4	15.6	0.5- ≥ 4	≥4	≥4	51.2
Amikacin	≤4-64	4	32	6.3	≤4-32	≤4	16	0
Gentamicin	≤1- ≥ 16	2	≥16	40.6	≤1- ≥ 16	4	≥16	45.7
Cefazolin	≥32	≥32	≥32	100	≥32	≥32	≥32	100
Cefotaxime	4- ≥ 64	≥64	≥64	100	32- ≥ 64	≥64	≥64	100
Cefoxitin	≥32	≥32	≥32	100	≥32	≥32	≥32	100
Ceftazidime	16- ≥ 32	≥32	≥32	100	≥32	≥32	≥32	100
Cefepime	0.25- ≥ 32	8	≥32	18.8	2- ≥ 32	16	≥32	46.5
Ciprofloxacin	0.06- ≥ 4	≥4	≥4	75.0	≤0.06- ≥ 4	≥4	≥4	79.1
Tigecycline	≤0.25-1	≤0.25	0.5	0	≤0.25- ≥ 4	≤0.25	0.5	7.0
Colistin	≤0.5-2	1	2	0	≤0.5- ≥ 4	≤0.5	1	2.3
SXT^a	0.06- ≥ 16	≥16	≥16	62.5	≤2/38- ≥ 4/76	≥4/76	≥4/76	76.7

^aSXT: Trimethoprim/sulfamethoxazole. Trimethoprim/sulfamethoxazole MICs are presented according to the concentration of trimethoprim in 2010.

ISSN: 1471-2334